Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL versus OXYTETRACYCLINE HYDROCHLORIDE.
DOXYCHEL vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic